Eli Lilly seeks to extend its winning streak in the general market to 6 years
Eli Lilly has outperformed the S&P 500 for five straight years as Wall Street realized its huge opportunity in obesity…
LILLY DRN
FDA Approves Eli Lilly's Zepbound Weight-Loss Drug for Sleep Apnea
An Eli Lilly & Co. Zepbound injection pen placed in the Brooklyn borough of New York, U.S., on Thursday, March…
Merck signs weight loss pills licensing agreement with Hansoh Pharma
Exterior view of the entrance to Merck headquarters on February 5, 2024 in Rahway, New Jersey. Spencer Platt | fake…
Eli Lilly's Zepbound Weight Loss Drug No Longer in Shortage
An injectable pen of Zepbound, Eli Lilly's weight loss drug, is on display in New York City on December 11,…
Ro to Offer Zepbound Vials of Weight Loss Drug Working with Eli Lilly
Patients will be able to access Zepbound single-dose vials in Ro Courtesy: Ro Direct-to-consumer healthcare startup Ro said Wednesday that…
The agreement with Novo Nordisk Catalent is closer to closing
A view of the Novo Nordisk logo at the company's office in Bagsvaerd, outside Copenhagen, Denmark, on March 8, 2024.…
Eli Lilly Zepbound causes more weight loss than Novo Nordisk Wegovy: trial
A merged image shows an injectable pen of Zepbound, Eli Lilly's weight-loss drug, and boxes of Wegovy, made by Novo…
Orders for Zepbound and Wegovy weight loss drugs double: GoodRx
A merged image shows an injectable pen of Zepbound, Eli Lilly's weight-loss drug, and boxes of Wegovy, made by Novo…
Wall Street mulls data on weight-loss drug Amgen
The Amgen logo is displayed outside of Amgen headquarters in Thousand Oaks, California, on May 17, 2023. Mario Tama |…
Eli Lilly's obesity drug beats rival in head-to-head trial, where Cramer thinks stock will be next
The new trial data has cemented Club's lead position behind Eli Lilly in the highly competitive anti-obesity drug race. Eli…